Growth factor releasing porous poly (epsilon-caprolactone)-chitosan matrices for enhanced bone regenerative therapy.
Drug releasing porous poly(epsilon-caprolactone) (PCL)-chitosan matrices were fabricated for bone regenerative therapy. Porous matrices made of biodegradable polymers have been playing a crucial role as bone substitutes and as tissue-engineered scaffolds in bone regenerative therapy. The matrices provided mechanical support for the developing tissue and enhanced tissue formation by releasing active agent in controlled manner. Chitosan was employed to enhance hydrophilicity and biocompatibility of the PCL matrices. PDGF-BB was incorporated into PCL-chitosan matrices to induce enhanced bone regeneration efficacy. PCL-chitosan matrices retained a porous structure with a 100-200 microm pore diameter that was suitable for cellular migration and osteoid ingrowth. NaHCO3 as a porogen was incorporated 5% ratio to polymer weight to form highly porous scaffolds. PDGF-BB was released from PCL-chitosan matrices maintaining therapeutic concentration for 4 week. High osteoblasts attachment level and proliferation was observed from PCL-chitosan matrices. Scanning electron microscopic examination indicated that cultured osteoblasts showed round form and spread pseudopods after 1 day and showed broad cytoplasmic extension after 14 days. PCL-chitosan matrices promoted bone regeneration and PDGF-BB loaded matrices obtained enhanced bone formation in rat calvarial defect. These results suggested that the PDGF-BB releasing PCL-chitosan porous matrices may be potentially used as tissue engineering scaffolds or bone substitutes with high bone regenerative efficacy.
Im
Su Yeon
SY
College of Pharmacy, Ewha Womans University, Seoul 120-750, Korea.
Cho
Seon Hye
SH
Hwang
Jeong Hyo
JH
Lee
Seung Jin
SJ
D000818:Animals; D000077214:Becaplermin; D001861:Bone Regeneration / Q000187:drug effects* / Q000502:physiology; D002208:Caproates / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D002455:Cell Division / Q000187:drug effects; D002686:Chitin / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use / Q000648:ultrastructure; D048271:Chitosan; D006133:Growth Substances / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007783:Lactones / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D008422:Materials Testing; D008855:Microscopy, Electron, Scanning; D010006:Osteoblasts / Q000187:drug effects* / Q000502:physiology / Q000648:ultrastructure; D010982:Platelet-Derived Growth Factor / Q000493:pharmacokinetics / Q000494:pharmacology; D016062:Porosity; D020574:Proto-Oncogene Proteins c-sis; D051381:Rats; D017207:Rats, Sprague-Dawley; D014407:Tumor Cells, Cultured
D002208:Caproates; D006133:Growth Substances; D007783:Lactones; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D002686:Chitin; D000077214:Becaplermin; C121056:caprolactone; D048271:Chitosan